Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 1, 2005, Pages 41-45

  Schneider, David J ^a   Baumann, Patricia Q ^a   Whitaker, Deborah A ^a   Sobel, Burton E ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Antiplatelet; Competitive inhibition; Dissociation constant; Glycoprotein IIb IIIa; Platelets; Rate of dissociation

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FLUOROCHROME; NITRATE; STATINE DERIVATIVE; THROMBIN RECEPTOR ACTIVATING PEPTIDE; TIROFIBAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISSOCIATION CONSTANT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; PATIENT CARE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SYMPTOMATOLOGY;

ADENOSINE DIPHOSPHATE; AGED; BINDING, COMPETITIVE; BLOOD PLATELETS; CORONARY ARTERIOSCLEROSIS; DATA INTERPRETATION, STATISTICAL; FIBRINOGEN; FLOW CYTOMETRY; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; IODINE RADIOISOTOPES; MALE; PEPTIDE FRAGMENTS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECEPTORS, THROMBIN; TICLOPIDINE; TYROSINE;

EID: 21444440241     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000162770.83324.17     Document Type: Article

References (25)

1. Nurden AT, Caen JP. An abnormal platelet glycoprotein pattern in three cases of Glanzmann thrombasthenia. Br J Haematol. 1974;28:253-260.
2. Phillips DR, Jenkins CSP, Luscher EF, et al. Molecular differences of exposed surface proteins on thrombasthenic platelet plasma membranes. Nature. 1975;257:599-600.
3. Coller BS. Interaction of normal, thrombasthenic, and Bernard-Soulier platelets with immobilized fibrinogen: defective platelet-fibrinogen interaction in thrombasthenia. Blood. 1980;55:169-178.
4. Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest. 1979;64:1393-1401.
5. Peerschke EI. The platelet fibrinogen receptor. Semin Hematol. 1985;22: 241-259.
6. Coller BS. Blockade of platelet GP IIb/IIIa receptors as an antithrombotic strategy. Circulation. 1995;92:2373-2380.
7. Kleiman NS, Raizner AE, Jordan R, et al. Differential inhibition of platelet aggregation induced by adenosine triphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GP IIb/IIIa inhibitors. J Am Coll Cardiol. 1995;26:1665-1671.
8. Cook JJ, Bednar B, Lynch JJ, et al. Tirofiban (Aggrastat™). Cardiovasc Drug Rev. 1999;17:199-224.
9. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol. 1997;80:11B-20B.
10. Moussa SA, Bennet JS. Platelets in health and disease: platelet GP IIb/IIIa structure and function: recent advances in antiplatelet therapy. Drugs of the Future. 1996;21:1141-1154.
11. Matthews JC. Fundamentals of Receptor, Enzyme, and Transport Kinetics. Boca Raton, FL: CRC Press, 1993.
12. Schneider DJ, Herrmann HC, Lakkis N, et al. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol. 2002;90:1421-1423.
13. Gilchrist IC, O'Shea JC, Kosoglou T, et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. Circulation. 2001;104:406-411.
14. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG: Blood clotting in Minimally altered whole blood. Blood. 1996;88:1-14.
15. Holmes MB, Sobel BE, Howard DB, et al. Differences between activation thresholds for platelet P-selectin glycoprotein IIb-IIIa expression and their clinical implications. Thromb Res. 1999;95:75-82.
16. Kabbani SS, Watkins MW, Ashikaga T, et al. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation. 2001;104:181-186.
17. Schneider DJ, Herrmann HC, Lakkis N, et al. Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. Am J Cardiol. 2003;91: 334-336.
18. Schneider DJ, Baumann PQ, Holmes MB, et al. Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin. Thromb Haemost. 2001;85:309-313.
19. Xia V, Wong T, Liu Q, et al. Optimally functional fluorescein isothiocyanate-labeled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation. Br J Haematol. 1996;93:204-214.
20. Keating FK, Whitaker DA, Sobel BE, et al. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes. Thromb Res. 2004;113:27-34.
21. Parise LV, Phillips DR. Reconstitution of the purified platelet fibrinogen receptor. Fibrinogen binding properties of the glycoprotein IIb-IIIa complex. J Biol Chem. 1985;260:10698-10707.
22. Huber W, Hurst J, Schlatter D, et al. Determination of kinetic constants for the interaction between the platelet glycoprotein IIb-IIIa and fibrinogen by means of surface plasmon resonance. Eur J Biochem. 1995;227:647-656.
23. The PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488-1497.
24. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436-443.
25. Boersma E, Akkerhuis KM, Theroux P, et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation. 1999;100:2045-2048.